A feeling of despair grips each of us when we face the problem of the management of intractable pain and pressure symptoms due to advanced incurable pelvic cancer. At this point the life expectancy may be brief, finances are depleted, and the patient's courage is nearly exhausted by the unrelenting course of his disease. In the interest of diminishing or alleviating the symptoms in the most rapid, least traumatic, and least expensive way possible, we have utilized nitrogen mustard introduced into the aorta in the manner to be described. Our experience in treating 52 patients over a seven-year period will be recounted here. The systemic use of HN2 has had widespread and beneficial application for many years. Our interest in its more localized and concentrated use by the arterial route was stimulated by the report of Klopp and associates in 1950 describing the experimental treatment of malignant tumors (17). Their experimentation followed the accidental intra-arterial administration of HN2 and the recognition of its potentiality. In animals they have shown radiomimetic tissue changes following the arterial distribution of nitrogen mustard, which could not be reproduced by intravenous doses of even lethal amounts of the drug. The rapid alleviation of symptoms in certain patients is consistent with the experimental evidence of Sugar and Kellner (21) that some cellular effect appears as early as ten minutes after injection of nitrogen mustard. The evidence of nuclear injury is seen microscopically in thirty to sixty minutes (21). Klopp states that the maximal microscopic cellular effect is demonstrable in twelve to twenty days. He observed some clinical reduction in the size of cervical and vaginal tumors approximately four days after intra-aortic injection of HN2 and a marked effect in eight days (18). The rapidity of action as compared with conventional radiation therapy provides an advantage which can well be utilized in dealing with intractable pain and pressure symptoms. Advanced malignant tumors of the head and neck, extremities, skin, and liver, as well as of the pelvis, have been treated with intra-arterial nitrogen mustard (4, 9, 13, 20). In those patients with sufficient life expectancy, if the skin tolerance dose has not been surpassed, the combined use of intra-aortic HN2 and external roentgen therapy has sound theoretical and experimental support (2, 3, 14, 16, 23). Fourteen cases receiving combined therapy are included in our group. method The intra-aortic administration of nitrogen mustard is carried out on a radiographic table in the radiology department approximately one hour after premedication with Demerol or scopolamine. General anesthesia is usually not needed.
Read full abstract